PGEN compared with NVCT: revenue, margins and what each company keeps, and the suppliers and customers both name

PGENPrecigen, Inc.

Mkt capRevenueRevenue

NVCTNuvectis Pharma, Inc.

Mkt capRevenueRevenue

Compare

PGENPrecigen, Inc.

NVCTNuvectis Pharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PGEN

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.4%▼−16.52%×1.01

Q2 FY26±21.3%▲+5.51%×0.26

May 14 '26±12.0%▲+10.84%×0.90

Q1 FY26±17.3%▲+25.48%×1.47

NVCT

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±19.8%▼−4.50%×0.23

Q2 FY26±38.9%▼−6.94%×0.18

= impliedPGEN realized, solidNVCT realized, hatchedOne scale, both sides: full bar = 84%× = |realized| ÷ impliedSource: market data

Q1 FY26

±56.7%

▲+9.22%

×0.16

Feb 11 '26±83.7%▲+0.46%×0.01

PGENPrecigen, Inc.

4.46▲+5.57%· post 4.46

Mkt cap$1.6BRevenue$74MQ3 FY26Revenue$10MFY25

NVCTNuvectis Pharma, Inc.

20.26▲+14.09%· post 21.33

ClosedNov 6 '26

Mkt cap$719.1MRevenue—Revenue—

Compare

ClosedNov 6 '26

PGENPrecigen, Inc.

NVCTNuvectis Pharma, Inc.

4.46▲+5.57%post 4.46

Price

20.26▲+14.09%post 21.33

$1.6B

Mkt cap

$719.1M

Q3 FY26$74M

Revenue

—

FY25$10M

Revenue

—

PGEN4.46▲+5.57%vsNVCT20.26▲+14.09%ClosedNov 6 '26